npj Vaccines (Oct 2022)

Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus

  • Saket Jhajharia,
  • Fritz Lai,
  • Heng Boon Low,
  • Kiren Purushotorman,
  • Bhuvaneshwari D/O Shunmuganathan,
  • Conrad En Zuo Chan,
  • Rachel Hammond,
  • Hans-Jürgen Netter,
  • Qingfeng Chen,
  • Seng Gee Lim,
  • Paul A. MacAry

DOI
https://doi.org/10.1038/s41541-022-00516-7
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Hepatitis B Virus (HBV) is a hepadnavirus that is the principal pathogen underlying viral liver disease in human populations. In this study, we describe the isolation and characterization of a fully human monoclonal antibody for HBV. This HuMab was isolated by a combinatorial screen of the memory B-cell repertoire from an acute/recovered HBV-infected patient. Lead candidate selection was based upon strong binding and neutralizing activity for live HBV. We provide a detailed biochemical/biophysical, and subclass characterization of its specificity and affinity against all of the principal HBV genotypes combined with a functional analysis of its in vitro activity. We also demonstrate its potential as a prophylaxis/therapy in vivo using human liver chimeric mouse models for HBV infection. These data have important implications for our understanding of natural human immunity to HBV and suggest that this potentially represents a new antibody-based anti-viral candidate for prophylaxis and/or therapy for HBV infection.